Truist Financial Corp Zymeworks Inc. Transaction History

Truist Financial Corp

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 22, 2022	SELL	$6.0 - $16.98 $153,000 - $432,990	-25,500 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$15.19 - $29.33 $7,595 - $14,665	-500 Reduced 1.92%	25,500 $418,000
Q3 2021 Nov 05, 2021	BUY	$27.35 - $37.28 $711,100 - $969,280	26,000 New	26,000 $755,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $872M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.